703-1258

completed

Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
703 (USA) · Dr. Okafor
consented 2012-07-20

AEs

Serious

Dropout signal

–

Adverse events

mild assessed

Mild APPLICATION SITE DERMATITIS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2012-09-04 (study day 47.0); relationship: PROBABLE

moderate assessed

Moderate APPLICATION SITE DERMATITIS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2012-09-04 (study day 47.0); relationship: PROBABLE

mild assessed

Mild APPLICATION SITE DERMATITIS — outcome: RECOVERED/RESOLVED; onset 2012-09-04 (study day 47.0); relationship: PROBABLE

moderate assessed

Moderate DIZZINESS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2001; relationship: NONE

mild assessed

Mild DIZZINESS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2001; relationship: NONE

mild assessed

Mild UPPER RESPIRATORY TRACT INFECTION — outcome: NOT RECOVERED/NOT RESOLVED; onset 2012-08-11 (study day 23.0); relationship: NONE

mild assessed

Mild UPPER RESPIRATORY TRACT INFECTION — outcome: RECOVERED/RESOLVED; onset 2012-08-11 (study day 23.0); relationship: NONE

Data queries

No data queries.